| Remission induction using arsenic trioxide in acute promyelocytic leukemia |
|
Chang-Ki Min |
|
1Department of Cardiology, Catholic University of Daegu College of Medicine, Daegu, Korea |
| 논평 : 급성전골수구성백혈병에서 arsenic trioxide를 중심으로 한 관해유도 |
|
민창기 |
|
|
|
|
|
|
| Abstract |
|
In acute promyelocytic leukemia (APL), all-trans retinoic acid (ATRA) triggers cell differentiation, while arsenic trioxide (ATO) generates partial differentiation and apoptosis. Standard initial treatment for patients with APL consists of chemotherapy, usually an anthracycline, and ATRA. It now appears that it is important to administer consolidation chemotherapy and to include ATRA in both the induction and maintenance phases of treatment. ATO, which is rarely associated with cardiac toxicity, has been shown to be the best reported salvage therapy for patients with APL who relapse following an initial remission. Moreover, ATO treatment can yield a high quality clinical/molecular remission and disease-free survival in relapsed as well as newly diagnosed APL patients. ATO may be effective as first-line treatment for APL, even though the results of ATO combination therapy with chemotherapy/ATRA requires further study. |
| Key Words:
Acute promyelocytic leukemia; Remission induction; All-trans retinoic acid; Arsenic trioxide |
|
PDF Links
Full text via DOI
Download Citation
